Conference Coverage
Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeks
Key clinical point: At 52 weeks, brodalumab met its PASI 100 endpoint compared with ustekinumab in the pivotal phase III AMAGINE-2 trial. Major...
Dr. Langley and Dr. Menter reported having financial relationships with Amgen and numerous other pharmaceutical companies.